The $15-per-share deal is a 43% premium to Icosavax’s closing share price yesterday and values the company at around $1.1 billion, of which $800 million is payable near-term, with the remainder tied to certain future achievements. It is due to close in the first quarter of 2024, subject to financial regulatory reviews.
Icosavax’s pipeline of respiratory disease vaccines is headed by IVX-A12, a virus-like particle (VLP) shot that targets both RSV and human metapneumovirus (hMPV), two major causes of serious respiratory tract infections, particularly in older people.
